Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).

Research paper from Europe PMC. Evidence status: source reported.

Published

2022-11-01

Source reference

MED:35429382

DOI

10.1093/infdis/jiac146

Jurisdiction

Not assessed

Licence

Bibliographic metadata only; article rights retained

Stirrup O, Krutikov M, Tut G, Palmer T, Bone D, Bruton R, Fuller C, Azmi B, Lancaster T, Sylla P, Kaur N, Spalkova E, Bentley C, Amin U, Jadir A, Hulme S, Giddings R, Nacer-Laidi H, Baynton V, Irwin-Singer A, Hayward A, Moss P, Copas A, Shallcross L. · J Infect Dis · brief-report; research support, non-u.s. gov't; journal article · Found via: ClinicalTrials.gov result publication

Source: https://europepmc.org/article/MED/35429382. Captured 2026-10-29.

Limitations: Listed by a ClinicalTrials.gov registration as a result publication of that study, and fetched by its PubMed ID. The registry's listing is the sponsor's statement; it does not confirm which data the paper used. Preprints may not be peer reviewed.